OncoResponse, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncoresponse.com
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1
Recruiting
- Conditions
- CancerTumor, SolidMalignant NeoplasmMetastatic CancerAdvanced Solid TumorCutaneous MelanomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- OncoResponse, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06090266
- Locations
- ๐บ๐ธ
NEXT Dallas, Irving, Texas, United States
๐บ๐ธNEXT Oncology, San Antonio, Texas, United States
๐บ๐ธNEXT Virginia, Fairfax, Virginia, United States
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
Phase 1
Recruiting
- Conditions
- CancerHead and Neck Squamous Cell CarcinomaMetastatic CancerLeiomyosarcomaTumor, SolidNon Small Cell Lung CancerMalignant NeoplasmAdvanced Solid TumorMelanomaLiposarcoma
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- OncoResponse, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05094804
- Locations
- ๐บ๐ธ
NEXT Oncology, San Antonio, Texas, United States
๐บ๐ธHonorHealth Research Institute, Scottsdale, Arizona, United States
๐บ๐ธNEXT Austin, Austin, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath